
    
      This is a single arm, Simon two-stage historically controlled study to compare the 4 month
      progression-free survival rate of patients with relapsed/refractory osteosarcoma treated with
      regorafenib in combination with nivolumab to those who received regorafenib alone (historical
      control).
    
  